Prevalence of UGT1A1*28 promoter polymorphism in the omani population: Implications for irinotecan treatment in GI cancer

被引：0
|
作者：
Al Ghoche, A. A. G. [1 ]
Al Zadjali, S. [2 ]
Pullanhi, A. [3 ]
Alfahdi, A. [3 ]
Al-Balushi, A. [2 ]
Al-Mahrouqi, N. [2 ]
Abu Omar, R. [3 ]
Salman, B. [4 ]
Almoundhri, M. [1 ]
机构：
[1] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Oncol Dept, Muscat, Oman
[2] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Res Labs, Muscat, Oman
[3] Sultan Qaboos Univ Hosp, Muscat, Oman
[4] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Pharm Dept, Muscat, Oman
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
525P
引用
收藏
页码：S208 / S209
页数：2
相关论文
共 50 条
  • [1] UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    Iyer L.
    Das S.
    Janisch L.
    Wen M.
    Ramírez J.
    Karrison T.
    Fleming G.F.
    Vokes E.E.
    Schilsky R.L.
    Ratain M.J.
    The Pharmacogenomics Journal, 2002, 2 (1) : 43 - 47
  • [2] Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan
    Maki Ando
    Yoshinori Hasegawa
    Yuichi Ando
    Investigational New Drugs, 2005, 23 : 539 - 545
  • [3] Pharmacogenetics of irinotecan:: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan
    Ando, M
    Hasegawa, Y
    Ando, Y
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) : 539 - 545
  • [4] UGT1A1*28 polymorphism linked to irinotecan-induced ADRs
    Reactions Weekly, 2008, 1207 (1) : 4 - 4
  • [5] The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
    Toffoli, Giuseppe
    Cecchin, Erika
    Corona, Giuseppe
    Russo, Antonio
    Buonadonna, Angela
    D'Andrea, Mario
    Pasetto, Lara Maria
    Pessa, Sergio
    Errante, Domenico
    De Pangher, Vincenzo
    Giusto, Mauro
    Medici, Michele
    Gaion, Fernando
    Sandri, Paolo
    Galligioni, Enzo
    Bonura, Salvatore
    Boccalon, Massimo
    Biason, Paola
    Frustaci, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3061 - 3068
  • [6] UGT1A1*28 polymorphism in ovarian cancer patients
    Cecchin, E
    Russo, A
    Corona, G
    Campagnutta, E
    Martella, L
    Boiocchi, M
    Toffoli, G
    ONCOLOGY REPORTS, 2004, 12 (02) : 457 - 462
  • [7] A population study on the UGT1A1*28 variant associated to irinotecan tolerance
    Roman, Ruth
    Colomer, Anna
    Erill, Nadina
    Verdú, Montse
    Ibañez, Rosa
    Cardo, Carles Cordon
    Puig, Xavier
    MODERN PATHOLOGY, 2006, 19 : 142 - 142
  • [8] UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
    Takano, Masashi
    Sugiyama, Toru
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2017, 10 : 61 - 68
  • [9] Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
    Liu, Xing-Han
    Lu, Jun
    Duan, Wei
    Dai, Zhi-Ming
    Wang, Meng
    Lin, Shuai
    Yang, Peng-Tao
    Tian, Tian
    Liu, Kang
    Zhu, Yu-Yao
    Zheng, Yi
    Sheng, Qian-Wen
    Dai, Zhi-Jun
    JOURNAL OF CANCER, 2017, 8 (04): : 691 - 703
  • [10] Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism
    Hazama, Shoichi
    Nagashima, Atsushi
    Kondo, Hiroshi
    Yoshida, Shin
    Shimizu, Ryoichi
    Araki, Atsuhiro
    Yoshino, Shigefumi
    Okayama, Naoko
    Hinoda, Yuji
    Oka, Masaaki
    CANCER SCIENCE, 2010, 101 (03) : 722 - 727
12345